Xylem Inc.

XYL

Held by 1 specialist biotech fund

Fund Holdings

AI Signal

**Signal Note:** Xylem (XYL) is a water infrastructure and analytics company—not a biotech firm—making this an unusual addition for Eventide's stated biotech-focused mandate.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Eventide Asset ManagementNEWFeb 13, 2026

Shares: 113,301Value: $15.4M

**Signal Note:** Xylem (XYL) is a water infrastructure and analytics company—not a biotech firm—making this an unusual addition for Eventide's stated biotech-focused mandate. This $15.4M position suggests a thematic pivot toward ESG/climate resilience themes rather than drug development, potentially signaling conviction in water scarcity as a secular tailwind but requiring clarification on fit with the fund's core biotech thesis.

More XYL Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CPRT1 fund DECK1 fund LITE1 fund NTAP1 fund GPI1 fund IMMX1 fund PI1 fund UNP1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: